Vistagen Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Vistagen Therapeutics

02/02/2024 21:13

* Vistagen Therapeutics Inc  VTGN.OQ   VTGN.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
5 (estimated) for the period ending December 31 2023
    * The South San Francisco California-based  company is
expected to
report a 202.5% increase in revenue to $544.5 thousand from $180
thousand a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Vistagen Therapeutics
Inc is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vistagen
Therapeutics Inc is $12.00​, above​ its last closing price
of $4.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.68       -0.68      -0.66     Beat    2.9
  2023                                                  
 Mar. 31 2023              -1.50      -1.75     Missed  -16.7​
 Dec. 31 2022  -2.40       -2.10      -1.50     Beat    28.6
 ​​Sep.        -1.72       -2.00      -2.40     Missed  -20
 30 2022                                                
 Jun. 30 2022  -2.25       -2.25      -3.00     Missed  -33.3​
 Mar. 31 2022  -1.50       -1.72      -2.70     Missed  -56.5
 Dec. 31 2021  -2.18       -2.17      -1.50     Beat    31
 This summary was machine generated February 2 at 21:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)